Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 1437173A

Drug Profile

GSK 1437173A

Alternative Names: GSK1437173A; Herpes zoster vaccine candidate (Hz/su) - GlaxoSmithKline; PED-HZ/su; QS-21 containing herpes zoster vaccine - GlaxoSmithKline/Agenus; recombinant adjuvanted Herpes Zoster vaccine; Shingrix; Varicella zoster vaccine - GlaxoSmithKline; Varicella zoster virus vaccine - GlaxoSmithKline; VZV gE; VZV vaccine - GlaxoSmithKline/Agenus

Latest Information Update: 31 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Japan Vaccine
  • Class Subunit vaccines; Varicella vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Herpes zoster

Most Recent Events

  • 31 Oct 2019 GlaxoSmithKline initiates a phase IIIb trial for Herpes zoster (Prevention) in Finland (IM) (EudraCT2019-001815-21)
  • 03 Jul 2019 GlaxoSmithKline plans the phase II ZOSTER-047 trial in Herpes zoster (Prevention, In infants, In children, In adolescents) in Italy, Spain and United Kingdom (IM) (NCT04006808) (EudraCT2019‐000607‐33)
  • 28 Jun 2019 GlaxoSmithKline initiates enrolment in a phase III trial for Herpes zoster (Prevention) Finland (IM) (EudraCT2016-000744-34)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top